GALWAY, Ireland--(BUSINESS WIRE)--Vivasure Medical ® (“Vivasure” or the “Company”), a company pioneering novel fully absorbable technology for percutaneous vessel closure, today announced the closing ...

Please provide your email address to receive an email when new articles are posted on . W.L. Gore and Associates announced its occluder device was approved by the FDA for percutaneous closure of ...

GALWAY, Ireland--(BUSINESS WIRE)--Vivasure Medical ®, a company pioneering novel fully absorbable technology for percutaneous vessel closure, today announced initial positive results from its U.S. IDE ...

Within the last 24 months, I have financial relationship(s) or affiliation(s) with a manufacturer, marketer, reseller, or distributor of a healthcare product or service involved in the management of ...

Debate: My Patient has a Blood Pressure of 150/90 Despite 2 Maximally Dosed Medications – Time for a Third Medication! Receive the the latest news, research, and presentations from major meetings ...

Ra Medical Systems Inc. launched a simple device that holds sutures more securely in place for closure of percutaneous wound sites during cardiac electrophysiology, structural heart and vascular ...

(RTTNews) - Shares of Catheter Precision Inc. (VTAK) are up over 65% at $4.36, following an encouraging regulatory news related to its LockeT wound closure device. LockeT is a suture retention device ...

On the basis of outcomes, there was no clear winner from a trial that directly compared two modern devices used in patients undergoing percutaneous left atrial appendage (LAA) closure. But the devices ...

SWISS-APERO is the first randomized clinical trial comparing Amulet with the new generation Watchman FLX device in terms of residual left atrial appendage (LAA) patency after percutaneous LAA closure ...

Please provide your email address to receive an email when new articles are posted on . Supraventricular arrhythmias may be underestimated in patients who have received percutaneous patent foramen ...